Class 1. Pulmonary Hypertension Associated with Inflammation Archives - Page 4 of 5

A very rare cause of pre-capillary pulmonary hypertension: The PAMI syndrome

Manuela Iseppi, Giulio Savonitto, Alberto Tommasini, Alessia Pin, Gianfranco Sinagra, Davide Stolfozienda Sanitaria Universitaria Giuliano-Isontina (ASUGI) and University of Trieste. University of Verona. Karolinska Institutet.Italy and Sweden Pulmonary CirculationPulm Circ 2023; 13: DOI: 10.1002/pul2.12300 AbstractWe report the first known case of PAMI syndrome associated with pulmonary arterial hypertension (PAH) with a positive response to cyclophosphamide and […]

A very rare cause of pre-capillary pulmonary hypertension: The PAMI syndrome Read More »

Identification of the shared gene signatures between pulmonary fibrosis and pulmonary hypertension using bioinformatics analysis

Hui Zhao, Lan Wang, Yi Yan, Qin-Hua Zhao, Jing He, Rong Jiang, Ci-Jun Luo, Hong-Ling Qiu, Yu-Qing Miao, Su-Gang Gong, Ping Yuan, Wen-Hui WuShanghai Pulmonary Hospital and Tongji University. University of Shanghai for Science and Technology. Shanghai Children’s Medical Center and Shanghai Jiao Tong University.China Frontiers in ImmunologyFront Immunol 2023; DOI: 10.3389/fimmu.2023.1197752 AbstractPulmonary fibrosis (PF) and

Identification of the shared gene signatures between pulmonary fibrosis and pulmonary hypertension using bioinformatics analysis Read More »

The small-molecule formyl peptide receptor biased agonist, Compound 17b, is a vasodilator and anti-inflammatory in mouse precision-cut lung slices

William R. Studley, Emma Lamanna, Katherine A. Martin, Claudia A. Nold-Perry, Simon G. Royce, Owen L. Woodman, Rebecca H. Ritchie, Cheng Xue Qin, Jane E. BourkeMonash University. Hudson Institute of Medical Research. Baker Heart and Diabetes Institute.Australia British Journal of PharmacologyBr J Pharmacol 2023; DOI: 10.1111/bph.16231 AbstractBackground and purpose: Pulmonary arterial hypertension (PAH), a rare but fatal

The small-molecule formyl peptide receptor biased agonist, Compound 17b, is a vasodilator and anti-inflammatory in mouse precision-cut lung slices Read More »

Myeloid-derived suppressor cells and pulmonary hypertension

Hui Zhang, Qi-Wei Li, Yuan-Yuan Li, Xue Tang, Ling Gu, Han-Min LiuWest China Second University Hospital and Sichuan University. The Fifth People’s Hospital of Chengdu. China Frontiers in ImmunologyFront Immunol 2023; 14: DOI: 10.3389/fimmu.2023.1189195 AbstractPulmonary hypertension (PH) is a chronic pulmonary vascular disorder characterized by an increase in pulmonary vascular resistance and pulmonary arterial pressure. The

Myeloid-derived suppressor cells and pulmonary hypertension Read More »

Acid ceramidase gene therapy ameliorates pulmonary arterial hypertension with right heart dysfunction

Michael G. Katz, Yoav Hadas, Adam Vincek, Lina Freage‑Kahn, Nataly Shtraizent, Jeko M. Madjarov, Peter Pastuszko, Efrat Eliyahu Icahn School of Medicine at Mount Sinai. SeneX Therapeutics Inc. Atrium Health Sanger Heart and Vascular Institute. Wake Forest School of Medicine. United States Respiratory ResearchRespir Res 2023; 24DOI: 10.1186/s12931-023-02487-2 AbstractBackground: Up-regulation of ceramides in pulmonary hypertension (PH), contributing to

Acid ceramidase gene therapy ameliorates pulmonary arterial hypertension with right heart dysfunction Read More »

Identification of ACKR4 as an immune checkpoint in pulmonary arterial hypertension

Chen-Yu Jiang, Li-Wei Wu, Yi-Wei Liu, Bei Feng, Lin-Cai Ye, Xu Huang, Yang-Yang He, Yi Shen, Yi-Fan Zhu, Xing-Liang Zhou, Dai-Ji Jiang, Hai-Kun Qi, Hao Zhang, Yi YanShanghai Children’s Medical Center. Henan University. Shanghaitech University. China Frontiers in ImmunologyFront Immunol 2023; DOI: 10.3389/fimmu.2023.1153573 AbstractObjective: Inflammation is recognized as a contributor in the development of pulmonary arterial hypertension

Identification of ACKR4 as an immune checkpoint in pulmonary arterial hypertension Read More »

Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management

Keval Yerigeri, Saurav Kadatane, Kai Mongan, Olivia Boyer, Linda LG Burke, Sidharth Kumar Sethi, Christoph Licht, Rupesh RainaCase Western Reserve University and The MetroHealth System. University of Oklahoma Health Sciences Center. Northeast Ohio Medical University. Necker-Enfants Malades Hospital. Kidney and Urology Institute. University of Toronto. Akron Children’s Hospital.United States, France and Canada Journal of Multidisciplinary

Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management Read More »

Microenvironmental regulation of T-cells in pulmonary hypertension

Lydie Plecita-Hlavata, Andrea Brazdova, MonikaKrivonoskova, Cheng-Jun Hu, Tzu Phang, Jan Tauber, Min Li, Hui Zhang, Konrad Hoetzenecker, Slaven Crnkovic, Grazyna Kwapiszewska, Kurt R. StenmarkCzech Academy of Sciences. Charles University. University of Colorado. Medical University of Vienna. Ludwig Boltzmann Institute for Lung Vascular Research. Institute for Lung Health.Czechia, United Stated, Austria and Germany Frontiers in ImmunologyFront

Microenvironmental regulation of T-cells in pulmonary hypertension Read More »

Percutaneous vascular stent implantation as treatment for central vascular obstruction due to fibrosing mediastinitis

Erin L. Albers, Meredith E. Pugh, Kevin D. Hill, Li Wang, James E. Loyd, Thomas P. DoyleVanderbilt University Medical Center.United States CirculationCirculation 2011; 123: 1391-1399DOI: 10.1161/CIRCULATIONAHA.110.949180 AbstractBackground: Fibrosing Mediastinitis (FM) is a rare complication of infection with Histoplasma capsulatum that can lead to obstruction of pulmonary and systemic vasculature and large airways, often resulting in significant morbidity

Percutaneous vascular stent implantation as treatment for central vascular obstruction due to fibrosing mediastinitis Read More »